- Poster presentation
- Open Access
Development of a single-tube, low-cost, analytical process to extract, separate and determine efavirenz and rifampicin plasma concentrations in HIV/TB co-infected patients
Journal of the International AIDS Society volume 13, Article number: P149 (2010)
Tuberculosis (TB) complicating HIV-1 infection is a persistent significant clinical concern, particularly in resource limited settings. Treatment of HIV-infected patients with TB often comprises efavirenz-containing antiretroviral regimens particularly when on TB treatment containing rifampicin. Although rifampicin may reduce EFV concentrations, little is known of the effect of the HIV virus or efavirenz on the pharmacokinetics of rifampicin, particularly in resource limited settings where the burden of disease exists. We aimed to develop a low-cost, simple analytical method for the accurate determination of efavirenz and rifampicin plasma concentrations.
Using high-performance liquid chromatography (HPLC) employing UV detection (1050 series quaternary pump, 1100 series autosampler, a diode array detector (DAD) and a 1200 series degasser), we developed and validated a single tube column-based assay for the detection of rifampicin and efavirenz. Data was acquired and analysed using Agilent Chemstation for LC 3D software.
Recovery for plasma samples spiked with the drugs were >90% for rifampicin and its metabolite deacetylrifampicin and >70% for efavirenz. Intra- and inter-assay precision relative standard deviation (RSD) values were <4% in all cases. The assay was validated on 300µl sample with a runtime of 10 minutes and both drugs measurable to concentrations of 100ng/mL.
This relatively easy, UV-based assay can accurately detect efavirenz and rifampicin concentrations within a clinically relevant concentration range using standard chromatography equipment, making it potentially applicable to resource limited settings.
About this article
Cite this article
Fox, D., O’Connor, R., Mallon, P. et al. Development of a single-tube, low-cost, analytical process to extract, separate and determine efavirenz and rifampicin plasma concentrations in HIV/TB co-infected patients. JIAS 13, P149 (2010). https://doi.org/10.1186/1758-2652-13-S4-P149
- Resource Limited Setting
- Single Tube
- Quaternary Pump